Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia

PHASE4CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

September 15, 2017

Primary Completion Date

May 31, 2023

Study Completion Date

May 31, 2023

Conditions
Schizophrenia Spectrum and Other Psychotic Disorders
Interventions
DRUG

Risperidone

Participants will meet with a study doctor physician once per week (about 3 times total) to monitor progress and side-effects of risperidone, which includes taking 4 assessments each time. After 4 weeks of taking Risperidone, participant will be assessed and scanned with the MRI/MRS scanner again.

Trial Locations (1)

10032

New York State Psychiatric Institute & Columbia University, New York

All Listed Sponsors
collaborator

New York State Psychiatric Institute

OTHER

collaborator

Columbia University

OTHER

collaborator

National Institute of Mental Health (NIMH)

NIH

lead

Weill Medical College of Cornell University

OTHER

NCT03323437 - Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia | Biotech Hunter | Biotech Hunter